Singapore’s HSA approves vericiguat (Verquvo) for use in high-risk heart failure patients with reduced ejection fraction

Kaye obtained her Masters of Pharmacy degree from the University College London and has spent the better part of her career as a clinical pharmacist in a tertiary care hospital. Her professional interests are centred on HEOR and HTA work, in hopes of ultimately influencing cost-effective decisions for patient care.